SMAC, COVID-19 (Plasma Therapy/Plasma Therapeutics) Theme Rises 5.77% Up
On the 7th, the COVID-19 (plasma treatment/plasma therapy) theme rose by 5.23% compared to the previous day, showing strength, while Esmak, a related stock drawing attention, surged by 5.77% compared to the previous day. Esmak is known as a manufacturer of touchscreen modules for mobile phones.
[Graph] Major stock price changes in the COVID-19 (plasma treatment/plasma therapy) theme
According to provisional data compiled at 11:46, foreign investors have been making large net purchases, buying 357,600 shares of Esmak.
[Table] Net purchases by foreigners and institutions (unit: 10,000 shares)
According to the analysis by Thinkpool RoboAlgorithm RASSI, Esmak ranked first (out of a total of 9 stocks) in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Esmak having a relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.
[Table] Top stocks by financial scores within the theme
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.
※ This article was generated in real-time by an automatic article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
